宠物抗癌药物市场规模、份额、成长分析（按生物体、治疗方法、给药途径、癌症类型和地区）- 产业预测，2025-2032 年

宠物抗癌药物市场规模预计将在 2023 年达到 4.02 亿美元，从 2024 年的 4.414 亿美元增长到 2032 年的 9.325 亿美元，在预测期内（2025-2032 年）的复合年增长率为 9.8%。

随着宠物饲主对宠物健康的认识不断提高，全球宠物抗癌药物市场正经历显着成长。这种有利于动物福利的转变正在推动对有效癌症治疗方案的需求增加。对此，业内公司正在开发专门针对宠物的新型治疗药物，旨在改善宠物罹患癌症的治疗效果和整体生活品质。此外，兽医肿瘤学的进步提高了我们对宠物癌症的认识，并导致了标靶治疗的产生。这种不断发展的市场环境反映了对动物的关怀与尖端科学进步之间的良好交汇，最终解决了对抗癌症的宠物的特殊医疗需求。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 监管分析

宠物癌症治疗药物市场规模（按类型）

• 市场概况
• 狗
• 猫
• 其他类型

宠物癌症治疗市场规模

• 市场概况
• 化疗
• 免疫疗法
• 标靶治疗
• 联合治疗

宠物癌症治疗药物市场规模（依给药途径）

• 市场概况
• 口服
• 注射

宠物癌症治疗药物市场规模（依癌症类型）

• 市场概况
• 淋巴瘤
• 肥大细胞癌
• 恶性黑色素瘤
• 乳腺腺癌和鳞状细胞癌
• 其他癌症

宠物癌症治疗药物市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Elanco Animal Health（US）
• Anivive Lifesciences（US）
• Regeneus（Australia）
• Qbiotics（Australia）
• Zoetis（US）
• VetDC（US）
• AB Science（France）
• Vet Cancer Group（US）
• VetriScience（US）
• Vetnostics（Australia）
• Veterinary Cancer Society（US）
• PetCure Oncology（US）
• Oasmia Pharmaceutical（Sweden）

结论和建议

Pet Cancer Therapeutics Market size was valued at USD 402.0 million in 2023 and is poised to grow from USD 441.4 million in 2024 to USD 932.5 million by 2032, growing at a CAGR of 9.8% during the forecast period (2025-2032).

The global pet cancer therapeutics market is experiencing significant growth due to heightened awareness among pet owners regarding their furry companions' health. This shift towards prioritizing animal welfare has catalyzed an increased demand for effective cancer treatment options. In response, industry players are innovating new therapeutics specifically designed for pets, aiming to enhance treatment outcomes and overall quality of life for those facing cancer diagnoses. Furthermore, advancements in veterinary oncology are deepening the understanding of pet cancer, leading to the creation of targeted therapies. This evolving market landscape reflects a promising intersection of compassion for animals and cutting-edge scientific progress, ultimately addressing the specialized healthcare needs of pets battling cancer.

Top-down and bottom-up approaches were used to estimate and validate the size of the Pet Cancer Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Pet Cancer Therapeutics Market Segments Analysis

Global Pet Cancer Therapeutics Market is segmented by Species, Therapy, Route of Administration, Cancer Type and region. Based on Species, the market is segmented into Dogs, Cats and Other species. Based on Therapy, the market is segmented into Chemotherapy, Immunotherapy, Targeted therapy and Combination therapy. Based on Route of Administration, the market is segmented into Oral and Injection. Based on Cancer Type, the market is segmented into Lymphoma, Mast cell cancer, Melanoma, Mammary and squamous cell cancer and Other cancer types. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Pet Cancer Therapeutics Market

One of the primary drivers propelling the global pet cancer therapeutics market is the growing trend of pet humanization. As pet owners increasingly perceive their pets as cherished family members, there is a heightened readiness to invest in sophisticated healthcare solutions, particularly for cancer treatments. This shift in perspective enhances the demand for effective and compassionate cancer therapies specifically designed for pets, fostering both innovation and expansion within the market. The commitment to providing superior care for beloved animals is fundamentally transforming the landscape of veterinary oncology, leading to advancements and a wider array of therapeutic options.

Restraints in the Pet Cancer Therapeutics Market

A major challenge facing the global pet cancer therapeutics market is the significant financial burden that cancer treatments impose on pet owners. The costs associated with various procedures and medications, including diagnostics, surgeries, radiation therapy, and pharmaceuticals, can be quite high. This economic strain may restrict many pet owners from accessing advanced cancer care options, ultimately forcing them to make tough choices regarding the level of treatment they can provide for their companions. Consequently, despite the growing awareness and demand for effective pet cancer therapeutics, the issue of affordability persists as a vital concern, affecting market dynamics and limiting the availability of these essential treatments.

Market Trends of the Pet Cancer Therapeutics Market

The global pet cancer therapeutics market is witnessing a notable trend centered around personalized treatment strategies. As pet owners and veterinarians increasingly acknowledge the distinct nature of each pet's cancer, there is a growing demand for customized therapeutic solutions, including precision medicine and targeted therapies. Innovations in diagnostics, such as genetic profiling and molecular testing, facilitate more accurate cancer diagnoses, enabling tailored treatment plans that align with the specific tumor characteristics of each pet. This focus on individualized care not only enhances treatment efficacy but also minimizes adverse side effects, reflecting a broader commitment to improving the quality of care and outcomes for pets battling cancer.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Analysis

Global Pet Cancer Therapeutics Market Size by Species & CAGR (2025-2032)

• Market Overview
• Dogs
• Cats
• Other species

Global Pet Cancer Therapeutics Market Size by Therapy & CAGR (2025-2032)

• Market Overview
• Chemotherapy
• Immunotherapy
• Targeted therapy
• Combination therapy

Global Pet Cancer Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injection

Global Pet Cancer Therapeutics Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Lymphoma
• Mast cell cancer
• Melanoma
• Mammary and squamous cell cancer
• Other cancer types

Global Pet Cancer Therapeutics Market Size & CAGR (2025-2032)

• North America (Species, Therapy, Route of Administration, Cancer Type)
  • US
  • Canada
• Europe (Species, Therapy, Route of Administration, Cancer Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Species, Therapy, Route of Administration, Cancer Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Species, Therapy, Route of Administration, Cancer Type)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Species, Therapy, Route of Administration, Cancer Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Elanco Animal Health (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anivive Lifesciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneus (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qbiotics (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zoetis (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VetDC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AB Science (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vet Cancer Group (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VetriScience (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetnostics (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Veterinary Cancer Society (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PetCure Oncology (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oasmia Pharmaceutical (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations